BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu S, Zhang Y, Wang G, Yang Q, Liu B, Zhang J, Li H, Wang G, Yang Y, Chen G. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2016;40:674-81. [DOI: 10.1016/j.clinre.2016.03.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Mohammed J, Akomolafe T, Aljurf M, Savani B, Hashmi SK. 'To treat or not to treat': raising awareness on the effects of graft versus host disease drugs on musculoskeletal system. Bone Marrow Transplant 2018;53:909-12. [PMID: 29371684 DOI: 10.1038/s41409-018-0095-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Grigg S, Gow P, Yeomans N. Sirolimus in Liver Transplant Recipients With Hepatocellular Carcinoma. J Invest Surg 2020;33:389-90. [PMID: 30457404 DOI: 10.1080/08941939.2018.1513103] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Li H, Yang Z, Li R, Lu S, Lu W. Regorafenib Combined With Sirolimus Achieves Successful Treatment of Diffuse Double Lung Metastasis After Liver Transplantation in Giant Liver Cancer Beyond Transplantation Criteria: A Case Report. Transplant Proc 2020;52:634-7. [PMID: 32035675 DOI: 10.1016/j.transproceed.2019.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zhang ZH, Li LX, Li P, Lv SC, Pan B, He Q. Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis. J Invest Surg. 2018;1-10. [PMID: 29557691 DOI: 10.1080/08941939.2018.1447053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
5 Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. Biochim Biophys Acta Rev Cancer. 2017;1868:564-570. [PMID: 29054475 DOI: 10.1016/j.bbcan.2017.10.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 87] [Article Influence: 14.4] [Reference Citation Analysis]
6 Lee KW, Kim SH, Yoon KC, Lee JM, Cho JH, Hong SK, Yi NJ, Han SS, Park SJ, Suh KS. Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial. J Clin Med 2020;9:E3264. [PMID: 33053849 DOI: 10.3390/jcm9103264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Ling S, Feng T, Zhan Q, Duan X, Jiang G, Shen T, Shan Q, Xu S, Ye Q, Liu P, Cen B, Zheng S, Xu X. Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria. Ann Transl Med 2020;8:80. [PMID: 32175373 DOI: 10.21037/atm.2020.01.10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zhao Y, Liu Y, Zhou L, Du GS, He Q. Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(9): 953-966 [PMID: 34621472 DOI: 10.4240/wjgs.v13.i9.953] [Reference Citation Analysis]
9 Ma T, Li QS, Wang Y, Wang B, Wu Z, Lv Y, Wu RQ. Value of pretransplant albumin-bilirubin score in predicting outcomes after liver transplantation. World J Gastroenterol 2019; 25(15): 1879-1889 [PMID: 31057301 DOI: 10.3748/wjg.v25.i15.1879] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Potter LM, Maldonado AQ, Lentine KL, Schnitzler MA, Zhang Z, Hess GP, Garrity E, Kasiske BL, Axelrod DA. Transplant recipients are vulnerable to coverage denial under Medicare Part D. Am J Transplant 2018;18:1502-9. [DOI: 10.1111/ajt.14703] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 Xu X, Chen J, Wei Q, Liu Z, Yang Z, Zhang M, Wang G, Gao J, Yang Z, Guo W, Xing T, Shao Z, Xie Q, Zheng S. Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China (2018 edition). Hepatobiliary & Pancreatic Diseases International 2019;18:307-12. [DOI: 10.1016/j.hbpd.2019.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
12 Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49:1260-1273. [PMID: 30989721 DOI: 10.1111/apt.15253] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]